Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation

被引：6

作者：

Carella, A. M. ^{[1
]}

机构：

[1] Azienda Osped Univ, Div Hematol, Genoa, Italy

来源：

LEUKEMIA | 2008年 / 22卷 / 05期

关键词：

D O I：

10.1038/leu.2008.94

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1090 / 1091

页数：2

共 7 条

[1] Specific human cellular immunity to bcr-abl oncogene-derived peptides [J].

Bocchia, M ;

Korontsvit, T ;

Xu, Q ;

Mackinnon, S ;

Yang, SY ;

Sette, A ;

Scheinberg, DA .

BLOOD, 1996, 87 (09) :3587-3592

[2] Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia [J].

Burchert, A ;

Wölfl, S ;

Schmidt, M ;

Brendel, C ;

Denecke, B ;

Cai, D ;

Odyvanova, L ;

Lahaye, T ;

Müller, MC ;

Berg, T ;

Gschaidmeier, H ;

Wittig, B ;

Hehlmann, R ;

Hochhaus, A ;

Neubauer, A .

BLOOD, 2003, 101 (01) :259-264

[3]

Butterfield LH, 1998, J IMMUNOL, V161, P5607

[4] Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia [J].

Carella, AM ;

Lerma, E ;

Corsetti, MT ;

Dejana, A ;

Basta, P ;

Vassallo, F ;

Abate, M ;

Soracco, M ;

Benvenuto, F ;

Figari, O ;

Podestà, M ;

Piaggio, G ;

Ferrara, R ;

Sessarego, M ;

Parodi, C ;

Pizzuti, M ;

Rubagotti, A ;

Occhini, D ;

Frassoni, F .

BLOOD, 1999, 93 (05) :1534-1539

[5] Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].

Clark, RE ;

Dodi, IA ;

Hill, SC ;

Lill, JR ;

Aubert, G ;

Macintyre, AR ;

Rojas, J ;

Bourdon, A ;

Bonner, PLR ;

Wang, LH ;

Christmas, SE ;

Travers, PJ ;

Creaser, CS ;

Rees, RC ;

Madrigal, JA .

BLOOD, 2001, 98 (10) :2887-2893

[6] Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia [J].

Molldrem, JJ ;

Lee, PP ;

Wang, CQ ;

Felio, K ;

Kantarjian, HM ;

Champlin, RE ;

Davis, MM .

NATURE MEDICINE, 2000, 6 (09) :1018-1023

[7] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia [J].

O'Hare, Thomas ;

Eide, Christopher A. ;

Deininger, Michael W. N. .

BLOOD, 2007, 110 (07) :2242-2249

← 1 →